Your browser doesn't support javascript.
COVID-19 mortality risk assessment: An international multi-center study.
Bertsimas, Dimitris; Lukin, Galit; Mingardi, Luca; Nohadani, Omid; Orfanoudaki, Agni; Stellato, Bartolomeo; Wiberg, Holly; Gonzalez-Garcia, Sara; Parra-Calderón, Carlos Luis; Robinson, Kenneth; Schneider, Michelle; Stein, Barry; Estirado, Alberto; A Beccara, Lia; Canino, Rosario; Dal Bello, Martina; Pezzetti, Federica; Pan, Angelo.
  • Bertsimas D; Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Lukin G; Operations Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Mingardi L; Operations Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Nohadani O; Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Orfanoudaki A; Operations Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Stellato B; Benefits Science Technologies, Boston, Massachusetts, United States of America.
  • Wiberg H; Operations Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Gonzalez-Garcia S; Sloan School of Management, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Parra-Calderón CL; Operations Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Robinson K; Operations Research Center, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
  • Schneider M; Institute of Biomedicine of Seville (IBIS), Virgen del Rocío University Hospital, CSIC, University of Seville, Seville, Spain.
  • Stein B; Institute of Biomedicine of Seville (IBIS), Virgen del Rocío University Hospital, CSIC, University of Seville, Seville, Spain.
  • Estirado A; Hartford HealthCare, Hartford, Connecticut, United States of America.
  • A Beccara L; Hartford HealthCare, Hartford, Connecticut, United States of America.
  • Canino R; Hartford HealthCare, Hartford, Connecticut, United States of America.
  • Dal Bello M; HM Hospitals, Madrid, Spain.
  • Pezzetti F; Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy.
  • Pan A; Azienda Socio-Sanitaria Territoriale di Cremona, Cremona, Italy.
PLoS One ; 15(12): e0243262, 2020.
Article in English | MEDLINE | ID: covidwho-965607
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Timely identification of COVID-19 patients at high risk of mortality can significantly improve patient management and resource allocation within hospitals. This study seeks to develop and validate a data-driven personalized mortality risk calculator for hospitalized COVID-19 patients. De-identified data was obtained for 3,927 COVID-19 positive patients from six independent centers, comprising 33 different hospitals. Demographic, clinical, and laboratory variables were collected at hospital admission. The COVID-19 Mortality Risk (CMR) tool was developed using the XGBoost algorithm to predict mortality. Its discrimination performance was subsequently evaluated on three validation cohorts. The derivation cohort of 3,062 patients has an observed mortality rate of 26.84%. Increased age, decreased oxygen saturation (≤ 93%), elevated levels of C-reactive protein (≥ 130 mg/L), blood urea nitrogen (≥ 18 mg/dL), and blood creatinine (≥ 1.2 mg/dL) were identified as primary risk factors, validating clinical findings. The model obtains out-of-sample AUCs of 0.90 (95% CI, 0.87-0.94) on the derivation cohort. In the validation cohorts, the model obtains AUCs of 0.92 (95% CI, 0.88-0.95) on Seville patients, 0.87 (95% CI, 0.84-0.91) on Hellenic COVID-19 Study Group patients, and 0.81 (95% CI, 0.76-0.85) on Hartford Hospital patients. The CMR tool is available as an online application at covidanalytics.io/mortality_calculator and is currently in clinical use. The CMR model leverages machine learning to generate accurate mortality predictions using commonly available clinical features. This is the first risk score trained and validated on a cohort of COVID-19 patients from Europe and the United States.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Algorithms / Hospital Mortality / SARS-CoV-2 / COVID-19 / Models, Biological Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America / Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2020 Document Type: Article Affiliation country: Journal.pone.0243262

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Algorithms / Hospital Mortality / SARS-CoV-2 / COVID-19 / Models, Biological Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: North America / Europa Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2020 Document Type: Article Affiliation country: Journal.pone.0243262